Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions - Wikidata - awgldk - TriplyDB

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

http://www.wikidata.org/entity/Q34023704

about

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.

P2860

Q35764587-2717B72F-5F1B-44D5-9C81-4C6DA1B7E14D Q37327310-02A9512B-6630-42F7-9AB2-9748BD8DD723 Q38451287-6A421B1C-567F-4F87-A817-7927850F48AE Q38845280-0B33C278-7412-47E1-B783-0B631E55D2FB Q38897134-BC688939-B270-4BC7-85AB-3890FC090E78 Q53762689-9DFB088F-41E5-4B13-BB6E-69A67D066A6B

P2860

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

http://www.wikidata.org/entity/Q34023704

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@ast

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@en

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@nl

type

label

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@ast

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@en

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@nl

prefLabel

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@ast

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@en

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@nl

P1433

Q34023704-8EA18D26-7C0D-434B-A6C6-92DA92FCDAD8

P1476

Q34023704-61632F4C-E967-4B56-9BB1-5BAACC89D674

P2093

Q34023704-189B6463-BD7F-4B11-AA9E-91B092011F8A

Q34023704-1B7A4AF6-56EF-41BD-A4FA-6D64990DC549

Q34023704-67D35722-DB36-440C-AE7F-0967238FB750

Q34023704-8957F201-45D0-4397-9FAC-7B172DCAC160

Q34023704-A985CFE5-AD8A-4F8E-AB1B-019F2E8B768B

Q34023704-CE45A717-B662-44B8-BBB9-E7F04F184FF6

P2860

Q34023704-02681B4F-342D-41EB-B6A0-8B37811C40A0

Q34023704-0420331C-FC43-4EAE-8788-88C41F5C2F82

Q34023704-0649DEC0-7B88-415C-832B-9960990B57D6

Q34023704-06D654F9-9B84-49FB-8605-D9A459668267

Q34023704-0FA061F1-CFE6-44DC-AE40-2D7D9AB94CCD

Q34023704-127DE239-DDF8-49F4-8AF5-381396CA05F3

Q34023704-1DD895C5-FA0E-4A44-B420-FC61B101240E

Q34023704-2176983A-8764-4004-9C55-2BC0969DE1E1

Q34023704-2656CCBA-ACE4-4338-9D46-4F7199B09FDE

Q34023704-2C40B152-4954-403E-A0A3-7AD12BBA92D6

P304

Q34023704-53A7965E-9455-4418-BAF2-E805056CDC0B

P31

Q34023704-2BC83B25-4707-47E7-B10B-6C755ABF027A

P356

Q34023704-0ACD196B-17E0-44F2-B432-DACE58AD71B5

P433

Q34023704-3E7E1100-5E6A-43A5-A021-0D3FA4463978

P478

Q34023704-5E031EC8-EA01-407F-882E-3B6A07BA57A4

P577

Q34023704-BB10C2B6-A2F5-459C-8BC7-F53DE30B62A2

P698

Q34023704-34C55AD8-6135-4606-87FF-8BB196508F0C

P932

Q34023704-AB119331-2C64-422B-9D5E-5CA722FB9F4F

P356

P1433

World journal of clinical oncology

P1476

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

@en

P2093

Enrique Dìaz Canton

http://www.w3.org/2001/XMLSchema#string

Gonzalo Recondo

http://www.w3.org/2001/XMLSchema#string

Martin Greco

http://www.w3.org/2001/XMLSchema#string

Matias E Valsecchi

http://www.w3.org/2001/XMLSchema#string

Màximo de la Vega

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Preoperative chemotherapy for women with operable breast cancer

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

P304

440-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V5.I3.440

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25114858

http://www.w3.org/2001/XMLSchema#string

P932

4127614

http://www.w3.org/2001/XMLSchema#string